https://www.thebodypro.com/category/hiv-policy-advocacy/tag/hepatitis-c

The Latest

Suraj Madoori, M.P.H., M.S.J., M.A. and Annette Gaudino

Will We Ever Have a Hepatitis C Vaccine? Two Activists Weigh in on the Challenges and Opportunities Ahead

A new injection of funding from Congress could be the catalyst for a future hepatitis C (HCV) vaccine.

By Terri Wilder, M.S.W.
integrase inhibitor

This Week in HIV Research: The Fast-Acting Power of Integrase

April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.

By Barbara Jungwirth and Myles Helfand
Annette Gaudino credit Jason Stern

As With HIV, New York State Was Set to Lead the Nation to End Hepatitis C. But Why Haven’t the Recommendations Been Made Public?

Activist and member of the state task force Annette Gaudino would like the public to know.

By Terri Wilder, M.S.W.
Promo Image

This Week in HIV Research: Do We Need New Statin Guidelines?

Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.

By Barbara Jungwirth and Myles Helfand
National Viral Hepatitis Action Plan and National HIV/AIDS Strategy

First Listening Session Held at USCA to Inform Updates to National HIV/AIDS Strategy and National Viral Hepatitis Action Plans

The U.S. Department of Health and Human Services was at USCA 2018 to hear from community members about their ideas on priorities and issues to be addressed in updates to the National HIV/AIDS Strategy and National Viral Hepatitis Action Plan, both of...

By HIV.gov
HHS's Corinna Dan Discusses Impacts of Viral Hepatitis and Equity Issues Img

HHS's Corinna Dan Discusses Impacts of Viral Hepatitis and Equity Issues

On the third day of the 2018 U.S. Conference on AIDS (USCA) Corinna Dan, R.N., M.P.H., viral hepatitis policy advisor at HHS's Office of HIV/AIDS and Infectious Disease Policy, shared information from her conference presentation.

By HIV.gov
Mavyret Approved as Eight-Week HCV Treatment Regimen, Including for Those With Mild Cirrhosis Img

Mavyret Approved as Eight-Week HCV Treatment Regimen, Including for Those With Mild Cirrhosis

A combination of glecaprevir and pibrentasvir (Mavyret), has been approved for hepatitis C treatment, for any genotype, with a treatment duration of only eight weeks -- four weeks less than most other current regimens.

By Sony Salzman
FDA Approves Vosevi for Hepatitis C Img

FDA Approves Vosevi for Hepatitis C

"Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past."

By U.S. Food and Drug Administration
FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection Img

FDA Approves Epclusa for Treatment of Chronic Hepatitis C Virus Infection

The U.S. Food and Drug Administration has approved Epclusa (sofosbuvir/velpatasvir) to treat adult patients with chronic hepatitis C virus. It is the first to treat all six major forms of HCV.

By U.S. Food and Drug Administration
Money Trail: Some Guidance for the Journey Img

In the Golden Age of the Hep C Cure, Discount Deals Tie Doctors' Hands

Who has the power to prescribe medications? In the ongoing struggle to cure the estimated 3.2 million people living with chronic hepatitis C virus (HCV) infection in the U.S., the answer may not be who you think.

By Mathew Rodriguez